Fasentin is an inhibitor of glucose transport. It partially inhibits glucose uptake in U937 and DU145 cells when used at concentrations ranging from 15 to 80 µM. Fasentin sensitizes PPC-1 prostate cancer and U937 leukemia cells, but not DU145 prostate cancer cells, to cell death induced by the Fas receptor activator CH-11 activating anti-Fas antibody (FAS). It also increases the expression of AspSyn and PCK2, genes associated with glucose deprivation, in PPC-1 cells and halts the cell cycle at the G0/G1 phase in U937 cells when used at concentrations of 50 and 40 µM, respectively.